Pharmacogenomic Test Assessment for Medication Management in the Advancement of Medicine
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pharmacogenomic Testing for Medication Management
- Sponsor
- ClinLogic LLC
- Enrollment
- 280000
- Locations
- 1
- Primary Endpoint
- Radar, Pharmocogenomic
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.
Detailed Description
Pharmocogenomic. A multicenter, observational study to evaluate the use of a Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known to be influenced by genetic variation.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Radar, Pharmocogenomic
Time Frame: The period of enrollment is anticipated to be 36 months with a 120- day follow-up period, for total study duration of approximately 40 months from first patient enrolled to completion of follow-up on the last patient in.
The primary endpoint of the study is the binary occurrence of meaningful change in drug regimen, defined in each patient when: 1. A genotype known to affect a drug the patient is taking is identified, \*and\* 2. The patient's treating physician makes at least one target drug regimen change, dose, substitution, or discontinuation. Change in drug dose, substitution, or discontinuation among patients with an identified genotype known to affect a drug the patient is taking as directed. This will be assessed by a quantitative survey.